FDA to order Juul e-cigarettes off market, reports say

A woman holds a Juul e-cigarette while walking in New York, Sept. 27, 2018. The U.S. Food and Drug Administration is preparing to order Juul to take its e-cigarettes off the market in the U.S., the Wall Street Journal reported on Wednesday.

A woman holds a Juul e-cigarette while walking in New York, Sept. 27, 2018. The U.S. Food and Drug Administration is preparing to order Juul to take its e-cigarettes off the market in the U.S., the Wall Street Journal reported on Wednesday. (Brendan McDermid, Reuters)


Save Story

Estimated read time: Less than a minute

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

WASHINGTON — The U.S. Food and Drug Administration is preparing to order Juul to take its e-cigarettes off the market in the United States, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.

Shares in tobacco giant Altria, which owns a 35% stake in Juul, were down 8% in morning trading after the report saying the agency's decision could arrive as early as Wednesday.

The verdict would come around two years after the vaping products maker applied for approval to keep selling e-cigarettes in the country, trying to prove that the products offered a net benefit to public health.

The FDA's review will decide whether they are effective in getting smokers to quit and, if so, whether the benefits to smokers outweigh the health damage to new users, including teenagers, who never smoked.

In October, the FDA allowed Juul rival British American Tobacco to market its Vuse Solo e-cigarettes and tobacco-flavored pods, making it the first-ever vapor product to get clearance from the health regulator.

Some experts, including brokerage Jefferies, at one point had expected Juul to get the FDA nod as well.

Altria and the FDA did not immediately respond to Reuters requests for comment.

Related stories

Most recent U.S. stories

Related topics

Reuters
    KSL.com Beyond Series
    KSL.com Beyond Business

    KSL Weather Forecast

    KSL Weather Forecast
    Play button